560 - Evaluation of Optimal Methylprednisolone Dose in Patients with Covid 19

Background:

Optimal dose of methylprednisolone in patients with moderate or severe COVID-19 is unclear. In our hospital, the use of 250-500 mg/day of methylprednisolone was frequent in the first wave of the pandemic. Lower dose were recommended in our protocol since September 2020. The aim was to evaluate the impact of methylprednisolone dose in the outcome of patients with moderate or severe COVID-19.

Methods:

This is a retrospective and observational study. Inclusion criteria: SARS-CoV-2 infection diagnosed by PCR, admission to our hospital between March 2020 and February 2021, SatO2 < 94% or SatO2/FiO2 < 447. Two treatment groups were compared: patients treated with 0.5-1.5 mg/kg/day (group 1) and patients treated with more than 1.5 mg/kg/day (group 2). The primary outcome analyzed was orotracheal intubation (OTI) or death from any cause at 28 days after admission. Differences in demographic, clinical and laboratory characteristics between treatment groups were analyzed. Variables with P < 0.1 were included in a binary logistic regression model, calculating a propensity score for assigning each patient to group 1 treatment. Bivariate analysis was performed to identify variables associated with worst outcome. Finally, Cox regression was performed including treatment group, propensity score as covariate and all the variables with P< 0.05 in the bivariate analysis.

Results:

285 patients were included, 197 in group 1 and 88 in group 2. The median age was 73 years, 52,3% were male. Mortality or OTI at 28 days was 24,9%. There was a higher proportion of patients in group 1 with COPD (9,6% vs 1.1%, P< 0.01), dyspnea (60.4% vs 45.5%, P=0.01), sepsis (22.8% vs 13.6%, P=0.07). Patients in group 2 had more impaired consciousness (18.2% vs 8.6%, P=0.02). The median of lymphocytes count was lower in group 1 (900 vs 1025, P=0.01). There were no differences in the primary outcome between treatment groups (26.1% in the group 2 vs 24.4% in the group 1, P=0.7).

Conclusion:

The use of high dose of methylprednisolone compared with intermediate dose is not associated with a better outcome in patients with moderate or severe COVID-19.

Presenting Author(s)

JL

Jose Luis Lamas Ferreiro, MD

MD
Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

J�

Judith Álvarez Otero, MD

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
FM

Fernando Maroto Piñeiro, MD

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
IA

Iolanda Abalde Ortega, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MR

Marta Rodríguez Villar, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SM

Sonia Morón Losada, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
IV

Irea Vidal González, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AC

Alejandra Canoa Rico, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
LF

Laura Fernández González, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
EF

Emilia Fernández Fernández, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MC

Marta Costas Vila, Resident

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AS

Ana Sanjurjo Rivo, MD

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
FF

Francisco Fernández Fernández, MD

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JP

Jose Manuel Paz Ferrín, MD

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AA

Alexandra Arca Blanco, MD

Ribera Povisa Hospital
Vigo, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MA

María Alonso, MD

RESIDENT
HOSPITAL POVISA
VIGO, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JD

Javier De la Fuente, MD, PhD

CHIEF OF INTERNAL MEDICINE
HOSPITAL POVISA
VIGO, Galicia, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.